Document Type
Perspective
Publication Title
Emory Corp. Governance & Accountability Rev. Perspectives
Publication Date
1-1-2018
Abstract
With marijuana remaining an illegal, Schedule I drug at the federal level, many legal questions and oddities surround the implications of federal law on state marijuana legalization. One point of apparent inconsistency is that while botanical marijuana continues to be highly disputed, synthetic versions of marijuana are legally produced and marketed nationwide by Big Pharma corporations. As the door continues to open for marijuana as a legal medical alternative, Big Pharma may be faced with a significant competitive adversary. There is some evidence to suggest that Big Pharma will respond by using its deep pockets not only to prevent legalization, but also to prevent research that would inform consumers of the beneficial effects of botanical marijuana vs. its synthetic counterpart.
First Page
127
Volume
5
Recommended Citation
Katharine Pickle,
Big Pharma Takes On Marijuana Legalization: The Synthetic Marijuana vs. Botanical Marijuana Paradox,
5
Emory Corp. Governance & Accountability Rev. Perspectives
127
(2018).
Available at:
https://scholarlycommons.law.emory.edu/ecgar-perspectives/11